Revelation Biosciences, Inc.
REVBHealthcare|Biotechnology|US
$3.89
+0.33 (+9.27%)
DCF Value
$106.03
Tangible Book / Share
$12.93
Cash / Share
$16.30
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06863467 Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease. | Renal Insufficiency, Chronic, Chronic Kidney Disease stage3 | P1P2 | Completed | 40 | RCT, Single-blind | Intravenous Gemini, Intravenous placebo |